Anika Moorjani
Role not yet determined Is this you? Add your title
Formerly Arkansas Affiliated with UAMS through 2021; recent publications list University of Oregon.
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Anika Moorjani's research investigates the pharmacological effects of natural product derivatives, focusing on their potential as antineoplastic agents. Her work includes the study of carbamate derivatives of colchicine, which have demonstrated potent activity against primary acute lymphoblastic leukemia and primary breast cancer cells in in vitro and ex vivo models. Moorjani also explores modified salinomycin analogs that target stem-like cells within breast cancer models, utilizing both 2D and 3D cultures. Her scholarship metrics include an h-index of 2 with 28 total citations across 2 publications. She has collaborated with researchers including Robert L. Eoff, Melanie C MacNicol, Angus M. MacNicol, and Alicja Urbaniak at the University of Arkansas for Medical Sciences, with whom she shares one publication each.
Metrics
- h-index: 2
- Publications: 2
- Citations: 28
Selected Publications
-
Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models (2021)
-
Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study (2020)
Collaboration Network
Top Collaborators
- Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study
- Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study
- Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study
- Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study
- Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study
- Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
Similar Researchers
Based on overlapping research topics